Assignee
ENTRADA THERAPEUTICS INC
US·6 granted patents·19 pending applications·75 citations·filing 2015–2024
Top patents by PatentIndex Score
25 records- 0197US11225506B2Cell penetrating peptides and methods of making and using thereofENTRADA THERAPEUTICS INC·Filed 2020·Granted Jan 18, 2022·14 cites·41 claims
- 0296US10815276B2Cell penetrating peptides and methods of making and using thereofENTRADA THERAPEUTICS INC·Filed 2016·Granted Oct 27, 2020·14 cites·40 claims
- 0396US10626147B2Cell penetrating peptides and methods of making and using thereofENTRADA THERAPEUTICS INC·Filed 2015·Granted Apr 21, 2020·39 cites·22 claims
- 0494US11987821B2Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathyENTRADA THERAPEUTICS INC·Filed 2021·Granted May 21, 2024·2 cites·18 claims
- 0592US11168310B2Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathyENTRADA THERAPEUTICS INC·Filed 2020·Granted Nov 9, 2021·6 cites·35 claims
- 0684US2025011367A1Cell penetrating peptides and methods of making and using thereofENTRADA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0782US2025115885A1Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathyENTRADA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0874US2022177523A1Cell penetrating peptides and methods of making and using thereofENTRADA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0967US2024084377A1Methods for the sequencing of phosphorodiamidate morpholino oligomers (pmo) and peptide-pmo (ppmo) conjugatesENTRADA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1066US2025011774A1Antisense compounds and methods for targeting cug repeatsENTRADA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1163US2026028630A1Hybrid oligonucleotidesENTRADA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1261US2024417429A1Compositions and methods for skipping exon 45 in duchenne muscular dystrophyENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1360US2025289851A1Cyclic peptides for delivering therapeuticsENTRADA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1460US2026098262A9Compounds and methods for skipping exon 44 in duchenne muscular dystrophyENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1559US2025228953A1Intracellular targeting of oligonucleotidesENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1659US2024245790A1Cyclic cell penetrating peptidesENTRADA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1758US12378267B2Synthesis of FMOC-protected morpholino monomers and oligomersENTRADA THERAPEUTICS INC·Filed 2022·Granted Aug 5, 2025·0 cites·20 claims
- 1858US2023312653A1Cyclic cell penetrating peptidesENTRADA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1958US2025051393A1Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activityENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2058US2023027739A1Antigen-binding and antigen degradation constructsENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2157US2025051780A1COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICINGENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2257US2024358845A1Compositions and methods for intracellular therapeuticsENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2355US2024247259A1Compositions and methods for modulating gene expressionENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2454US2025243244A1Cyclic cell penetrating peptidesENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2549US2023020092A1Compositions for delivery of antisense compoundsENTRADA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →